Expression and activity of extracellular signal-regulated kinase-1/2 (ERK1/2) in normal tissues and human thyroid tumors

TitleExpression and activity of extracellular signal-regulated kinase-1/2 (ERK1/2) in normal tissues and human thyroid tumors
Publication TypeJournal Article
Year of Publication2016
AuthorsGuda, BB, Pushkarev, VM, Zhuravel, OV, Kovalenko, AYe., Pushkarev, VV, Tarashchenko, YM, Zurnadzhy, LY, Kovzun, OI, Tronko, MD
Abbreviated Key TitleDopov. Nac. akad. nauk Ukr.
DOI10.15407/dopovidi2016.01.105
Issue1
SectionMedicine
Pagination105-109
Date Published1/2016
LanguageUkrainian
Abstract

We studied the expression and the activation of a main effector kinase of the mitogenic cascade — extracellular signal-regulated kinase 1/2 (ERK 1/2) — in normal tissues, benign and malignant human thyroid tumors. The total content of ERK in all investigated tumors except for goiter was significantly lower in tumor tissues compared with normal tissues. ERK activity was almost completely inhibited in tumors, but not in normal tissue. Thus, ERK activity is not associated with proliferative processes in a tumor tissue of a thyroid gland. Possible mechanisms of inhibiting the activity of the mitogenic signaling cascade in thyroid tumors are discussed.

Keywordsbenign and malignant tumors, extracellular signal-regulated kinase-1/2, thyroid
References: 
  1. Guda B. B., Pushkarev V. V., Zhuravel O. V. et al. Reports of the National Academy of Sciences of Ukraine, 2015, 10: 93–97 (in Ukrainian). doi: https://doi.org/10.15407/dopovidi2015.10.093
  2. Beeram M., Patnaik A., Rowinsky E. K. J. Clin. Oncol., 2005, 23: 6771–6790. doi: https://doi.org/10.1200/JCO.2005.08.036, PMid:16170185
  3. McCubrey J. A., Steelman L. S., Chappell W. H. et al. Biochim. Biophys. Acta, 2007, 1773, No 8: 1263–1284. doi: https://doi.org/10.1016/j.bbamcr.2006.10.001, PMid:17126425 PMCid:PMC2696318
  4. Caronia L. M., Phay J. E., Shah M. H. Clin. Cancer Res., 2011, 17, No 24: 7511–7517. doi: https://doi.org/10.1158/1078-0432.CCR-11-1155, PMid:21900390
  5. Xing M. Nat. Rev. Cancer, 2013, 13: 184–199. doi: https://doi.org/10.1038/nrc3431, PMid:23429735 PMCid:PMC3791171
  6. Montagut C., Settleman J. Cancer Lett., 2009, 283, No 2: 125–134. doi: https://doi.org/10.1016/j.canlet.2009.01.022, PMid:19217204
  7. Milosevic Z., Pesic M., Stankovic T. et al. Transl. Res., 2014, 164, No 5: 411–423. doi: https://doi.org/10.1016/j.trsl.2014.06.005, PMid:25016932
  8. Wortzel I., Seger R. Genes & Cancer, 2011, 2, No 3: 195–209. doi: https://doi.org/10.1177/1947601911407328, PMid:21779493 PMCid:PMC3128630
  9. Park J. I., Strock C. J., Ball D. W., Nelkin B. D. Mol. Cell. Biol., 2003, 23, No 2: 543–554. doi: https://doi.org/10.1128/MCB.23.2.543-554.2003, PMid:12509453 PMCid:PMC151536
  10. Park J. I. Front. Biol. (Beijing), 2014, 9, No 2: 95–103. doi: https://doi.org/10.1007/s11515-014-1299-x, PMid:24999356 PMCid:PMC4079089
  11. Hong S. K., Yoon S., Moelling C. et al. J. Biol. Chem., 2009, 284, No 48: 33006–33018. doi: https://doi.org/10.1074/jbc.M109.012591, PMid:19805545 PMCid:PMC2785141
  12. Wu P. K., Hong S. K., Veeranki S. et al. Mol. Cell. Biol., 2013, 33, No 20: 4051–4067. doi: https://doi.org/10.1128/MCB.00021-13, PMid:23959801 PMCid:PMC3811686